Barr Tamoxifen Sales Benefit From Zeneca's Risk Reduction Campaign

Barr's tamoxifen sales increased by more than one-third in the third quarter of fiscal 1999, Barr CEO Bruce Downey said during an April 21 conference call.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet